TP10 Use in Patients With C3 Glomerulopathy (C3G)

Summary

The purpose of this study is to evaluate the safety of repeated TP10 dosing in pediatric and adult patients with C3G and to evaluate the activity of TP10 in pediatric and adult patients with C3G, as measured by the proportion of patients with normalization of serum C3, serum C3 breakdown products, or alternative pathway (AP) complement activity.

Timeline

Start

2014-11

Primary completion

2016-10

Completion

2016-10

Outcome

Outcome not reported

Stopped (Enrollment): “no recruitment”

Drugs

Indications